Bipyridylaminopyridines as Syk inhibitors

US9145391B2 · kind B2 · utility

Assignees

• Merck Sharp & Dohme LLC · US
• Merck Canada Inc. · CA

Inventors

• Denis Deschenes · Dorval, CA
• Michael D. Altman · Cambridge, US
• John Michael Ellis · Needham, US
• Christian Fischer · Natick, US
• Andrew M. Haidle · Cambridge, US
• Solomon D. Kattar · Arlington, US
• Alan B. Northrup · Reading, US
• Adam J. Schell · Decatur, US
• Graham F. Smith · Sudbury, US
• Brandon M. Taoka · Brookline, US
• Corey E. Bienstock · Natick, US
• Maria Emilia Di Francesco · Houston, US
• Anthony Donofrio · Cambridge, US
• Scott Peterson · Woodinville, US
• Kerrie Spencer · Woonsocket, US
• James P. Jewell · Jersey City, US
• Amjad Ali · Freehold, US
• David Jonathan Bennett · Watertown, US
• Qun Dang · Westfield, US
• John S. Wai · Harleysville, US

Key dates

• Filing date: May 4, 2012
• Grant date: Sep 29, 2015
• Expiry date: May 4, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention provides novel pyrimidine amines of formula I which are potent inhibitors of spleen tyrosine kinase, or are prodrugs thereof, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD and rheumatoid arthritis and cancer.